Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04073615 · ClinicalTrials.gov registry record · Phase 1
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
A Phase 1 study, sponsored by Elevar Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT04073615 is a Phase 1 study that was terminated before completion, run by Elevar Therapeutics. The registered enrollment target is 29 participants.
The verdict
NCT04073615, a Phase 1 study, was terminated before completion, sponsored by Elevar Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in participants with mCRC.
Interventions
- DRUG Trifluridine/Tipiracil
- DRUG Rivoceranib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04073615
The ClinicalTrials.gov registry entry for NCT04073615 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elevar Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trifluridine/Tipiracil is the first listed.
NCT04073615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04073615 about?
NCT04073615 is a clinical study titled "A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)". The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in participants with mCRC.
What is the current status of trial NCT04073615?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2019-11-18. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT04073615?
The interventions under investigation include: Trifluridine/Tipiracil (DRUG), Rivoceranib (DRUG).
Who is sponsoring clinical trial NCT04073615?
This trial is sponsored by Elevar Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.